Full Description

This paper examines the findings from three research projects that dealtwith the passage of endocrine disrupting compounds (EDCs) and pharmaceuticals and personal care products (PPCPs) compounds through conventional wastewater andadvanced reuse treatment processes.The first study was an evaluation, funded by the Water Environment Research Foundation, of thepassage of PPCP compounds through the aqueous phase of full-scale wastewaterfacilities located in the arid Southwestern United States. The data demonstrate howcompound passage can be related to the solids retention time (SRT) of the activatedsludge process. The study also evaluated the impact of wastewater granular media filtersand MF/RO that were part of some of the study process trains and compared performanceof a full-scale activated sludge facility with side-by-side operation of a pilot MBR.The second study was an evaluation of monitoring methods to ensure the integrity ofreverse osmosis (RO) membranes during water reclamation predominantly funded by theCalifornia Department of Water Resources. RO pilot testing was performed by the Cityof San Diego and MWH using tertiary treated wastewater from the North City WaterReclamation Plant located in San Diego County, California. Presented results focus onthe passage of EDC and PPCP compounds through four different vendor supplied ROmembranes and the impact of RO staging and membrane breaching on compoundpassage.The third study was part of an alternative water source program funded by the City of SanDiego Water Department in partnership with the San Diego County Water Authority andthe Metropolitan Water District of Southern California. The work, performed earlier atthe same site location as the second study, evaluated UV/peroxide treatment as anadditional barrier against the passage of EDCs and PPCPs in RO treated tertiarywastewater effluent. The RO effluent was spiked with N-nitrosodimethylamine (NDMA)and eight (8) EDC/PPCP target compounds in order to determine the reduction in thepassage of EDCs and PPCPs at the dose needed to achieve one-log reduction of NDMA. Includes 11 references, tables, figure.

Product Details

Edition: Vol. - No. Published: 11/01/2007 Number of Pages: 15File Size: 1 file , 260 KB